By Billy Candra 
A groundbreaking new study suggests a transformative shift in breast cancer screening practices, advocating for an individualized, risk-adapted approach over the long-standing model of routine annual mammograms for all women. The comprehensive research, known as the WISDOM study, indicates that by aligning screening frequency with a woman’s unique risk profile, it is possible to significantly reduce the incidence of advanced cancer diagnoses while ensuring that individuals receive appropriate and timely surveillance. This personalized strategy not only enhances safety and effectiveness but also promises to optimize healthcare resources.
A Paradigm Shift in Screening Guidelines
The pivotal findings are derived from data collected from 46,000 women across the United States who participated in the initial phase of the WISDOM study. Coordinated by the University of California, San Francisco (UCSF), the study challenges the traditional age-based screening guidelines that have largely governed breast cancer detection for decades. Instead, it proposes a system rooted in a thorough evaluation of individual risk, incorporating a multitude of factors beyond just age. This move represents a potential fundamental re-evaluation of how healthcare providers and patients approach breast cancer prevention and early detection.
"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," stated Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. Dr. Esserman’s remarks underscore the profound implications of the research, which was published on December 12 in the prestigious JAMA journal and simultaneously presented at the San Antonio Breast Cancer Symposium, a key event for advancements in breast cancer research. She further elaborated, "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."
For generations, breast cancer has remained the most prevalent cancer diagnosed among women in the United States, excluding non-melanoma skin cancers. The incidence rate in the U.S. is approximately 13% over a woman’s lifetime, meaning about 1 in 8 women will develop invasive breast cancer. Despite this significant public health burden, screening guidelines historically operated on the assumption of a relatively uniform risk across the female population, with age being the primary determinant for initiating and continuing mammography. However, a growing body of evidence has long demonstrated that an individual’s risk for breast cancer can vary substantially, influenced by a complex interplay of genetic predispositions, family history, breast density, reproductive history, lifestyle choices, and environmental exposures. The WISDOM study directly addresses this variability, seeking to create a more nuanced and effective screening regimen.
The Genesis and Evolution of Breast Cancer Screening
The concept of mammography for breast cancer detection emerged in the mid-20th century, gaining widespread acceptance by the 1980s. Early guidelines often recommended annual mammograms starting at age 40 or 50, based on observational studies showing a reduction in mortality rates. This "one-size-fits-all" approach, while instrumental in saving countless lives by detecting cancers at earlier, more treatable stages, has not been without its criticisms. Concerns have long been raised regarding potential harms, including false positives leading to unnecessary biopsies and anxiety, overdiagnosis of indolent cancers that might never have become life-threatening, and cumulative radiation exposure.
The WISDOM (Women Informed to Screen Depending On Measures of Risk) study was launched in 2016, specifically designed to address these limitations by directly comparing the traditional annual mammography strategy with a dynamic, risk-based screening protocol. The study enrolled over 80,000 women in total, with the initial phase reporting on 46,000 participants. This ambitious undertaking represented a collaborative effort involving numerous institutions across the U.S., including UC Los Angeles, UC Irvine, UC San Diego, and other prominent medical centers, with UCSF serving as the coordinating hub. The study’s design was groundbreaking, allowing participants to either be randomized to one of the two screening arms or join an observational group where they could choose their preferred strategy, providing invaluable insight into patient acceptance of personalized care.
Unpacking the WISDOM Study Methodology: A Tailored Approach
The core of the WISDOM study’s methodology lay in its sophisticated risk assessment model. Researchers utilized well-validated tools to categorize participants into four distinct risk groups, moving far beyond mere age. These comprehensive evaluations integrated a diverse set of data points:
- Age: While not the sole determinant, age remained a crucial factor in risk algorithms.
- Genetic Information: This included testing for known pathogenic variants like BRCA1 and BRCA2, as well as the innovative use of polygenic risk scores (PRS).
- Lifestyle Factors: Elements such as diet, physical activity levels, alcohol consumption, and body mass index (BMI) were considered.
- Health History: Personal medical history, including prior benign breast disease, and family history of breast cancer were factored in.
- Breast Density: Denser breast tissue can mask tumors on mammograms and is an independent risk factor for breast cancer.
Based on this granular risk evaluation, participants received tailored screening recommendations:
- Lowest Risk Group (26% of participants): These women were advised to delay routine screening until age 50 or until an algorithmic reassessment indicated their risk level had risen to that of an average 50-year-old woman. This approach aims to reduce unnecessary screening for a significant portion of the population, thereby mitigating potential harms like false positives and anxiety.
- Average Risk Group (62% of participants): For this majority, a biennial (every two years) mammogram schedule was recommended, aligning with some existing guidelines for average-risk women and aiming for a balance between detection and reducing over-screening.
- Elevated Risk Group (8% of participants): Women in this category were advised to undergo annual mammograms, recognizing their higher probability of developing breast cancer.
- Highest Risk Group (2% of participants): This segment, identified as having the most significant risk, received the most intensive screening protocol: twice-yearly screening, alternating between mammography and magnetic resonance imaging (MRI), regardless of age. MRI is known for its higher sensitivity in detecting cancers, particularly in dense breasts or in individuals with strong genetic predispositions.
Personalized Prevention and Support for High-Risk Individuals
Beyond tailored screening schedules, the WISDOM study also incorporated a crucial element of personalized prevention for women identified with elevated or highest risk. These participants received customized guidance aimed at actively lowering their chances of developing breast cancer. This support included access to an online decision-making tool specifically focused on breast health, providing evidence-based information and resources. Moreover, direct contact with a dedicated breast health specialist ensured personalized advice and addressed individual concerns. Recommendations encompassed actionable lifestyle changes, such as improving dietary habits and increasing physical activity, both of which are known to influence cancer risk. Discussions also included the potential use of medications, such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors, which can effectively reduce breast cancer risk in certain high-risk populations.
Importantly, the study meticulously tracked outcomes to ensure the personalized screening approach did not inadvertently lead to a higher rate of late-stage cancer diagnoses. The results confirmed that the risk-based strategy was as effective as traditional screening in detecting cancers at early, treatable stages, or even more effective in some instances by directing more intensive screening to those who needed it most. This finding is critical, as it addresses a major concern that moving away from universal annual screening might compromise early detection for some individuals.
A compelling indicator of the personalized approach’s potential widespread acceptance came from the observational group within the study. Women who chose not to be randomized into either the traditional or risk-based screening arms were given the option to select their preferred strategy. A remarkable 89% of these participants opted for risk-based screening, suggesting a strong preference for and confidence in a more individualized approach among informed patients.
Dr. Jeffrey A. Tice, MD, a UCSF professor of Medicine and co-author specializing in the development and evaluation of breast cancer risk assessment tools, emphasized the efficiency of this new paradigm: "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer." This reallocation of resources holds significant implications for healthcare economics and public health strategy.
Expanding Genetic Testing Beyond Family History
A particularly illuminating aspect of the WISDOM study involved its approach to genetic testing. Since its inception, WISDOM has expanded its enrollment to include women as young as 30, specifically to identify those who might face an increased risk of aggressive early-onset cancers due to inherited genetic variants. This proactive screening for genetic predispositions represents a significant departure from current clinical guidelines.
One of the study’s most notable and impactful findings was the detection of genetic variants linked to higher breast cancer risk in women who reported no family history of the disease. A substantial 30% of women who tested positive for such variants fell into this category. Under prevailing clinical guidelines, many of these women would not typically qualify for genetic testing, which is often restricted to individuals with a strong family history of breast or ovarian cancer, specific ethnic backgrounds, or a personal history of early-onset cancer. This finding strongly advocates for broader access to genetic testing, potentially identifying a significant cohort of high-risk women who would otherwise remain unaware of their elevated risk.
Beyond the well-known pathogenic variants like BRCA1 and BRCA2, the WISDOM study also explored the utility of evaluating smaller DNA changes, which can be combined to create a polygenic risk score (PRS). A PRS is a quantitative measure that estimates an individual’s genetic susceptibility to a particular disease based on the cumulative effect of many common genetic variants, each having a small effect. This innovative approach significantly improved the precision of risk predictions within the study, leading to 12% to 14% of participants being reassigned to a different risk category based on their PRS. This highlights the power of integrating advanced genomic data into comprehensive risk assessments.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," noted Allison S. Fiscalini, MPH, of UCSF, who serves as the director of the Athena Breast Health Network and the WISDOM study. She underscored the potential impact, stating, "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."
Broader Implications and the Path Forward
The findings from the WISDOM study carry profound implications for public health, clinical practice, and healthcare policy. A move towards personalized screening could lead to:
- Improved Health Outcomes: By directing intensive screening to those at highest risk, the study promises to detect more aggressive cancers earlier, potentially improving survival rates. Conversely, reducing unnecessary screening for lower-risk women could decrease the harms associated with overdiagnosis and false positives.
- Reduced Healthcare Costs: Universal annual mammography is a costly endeavor. By tailoring screening frequency, resources could be reallocated more efficiently, potentially leading to significant savings for healthcare systems and insurers. For instance, the cost of an average mammogram can range from $100-$300, and scaling down unnecessary screenings for millions of women could free up substantial funds.
- Patient Empowerment and Reduced Anxiety: Women receiving a personalized risk assessment can make more informed decisions about their health. For lower-risk women, less frequent screening could alleviate anxiety associated with unnecessary procedures. For higher-risk women, clear guidance and proactive prevention strategies can offer reassurance and a sense of control.
- Policy and Guideline Revisions: The robust evidence presented by WISDOM provides a strong impetus for major medical organizations, such as the American Cancer Society, the U.S. Preventive Services Task Force (USPSTF), and the American College of Radiology, to re-evaluate and potentially revise their breast cancer screening guidelines. While such changes are often gradual and subject to extensive review, this study offers a compelling new direction.
- Ethical Considerations and Equity: As personalized screening becomes more prevalent, it will be crucial to address ethical considerations, particularly regarding equitable access to advanced genetic testing and personalized prevention strategies across all socioeconomic and demographic groups. Ensuring that disparities in care do not widen will be a key challenge.
The research journey for personalized risk assessment continues with the WISDOM 2.0 study, which is actively enrolling participants. This next phase aims to further refine risk assessment models, focusing on better identifying women who face a higher likelihood of developing aggressive breast cancers. The ultimate goal remains to provide these individuals with screening and prevention strategies that are precisely tailored to their long-term health needs, moving closer to a future where breast cancer detection and prevention are as individualized as the women they serve.
The extensive list of co-authors from UCSF and other collaborating institutions, including Dr. Laura J. van ‘t Veer, Dr. Maren T. Scheuner, Dr. Alexander D. Borowsky, and many others, underscores the collaborative and multidisciplinary nature of this landmark research. Funding from prominent organizations such as the Patient-Centered Outcomes Research Institute, the National Cancer Institute, and the Breast Cancer Research Foundation highlights the critical importance of this work in advancing women’s health. The WISDOM study stands as a testament to the power of precision medicine, offering a promising new blueprint for a more effective, safer, and truly patient-centered approach to breast cancer screening.
